drugset / Trial / NCT01820195

N-Acetyl Cystein and Contrast Nephropathy

NCT01820195

RandomizedParallel-groupDouble-blindPrevention

Summary

There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different end points, different type and dose of N-Acetyl Cystein administration and finally different prophylactic measures other than N-Acetyl Cystein. The investigators try to enroll a double blind double dummy study with a good power to compare the effect of this drug both in the form of oral and intravenous against the placebo in preventing the contrast nephropathy in the patients whom undergo coronary angiography/angioplasty.

Timeline

Start
2013-03
Primary completion
2014-08
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcystein Unknown 600 mg Oral
Comparator N-acetylcystein Unknown 1200 mg Oral